INNOVEOX gets Charles Rosier as new Partner and TOTAL EP as first client - Afrik-news.com : Africa news, Maghreb news - The african daily newspaper


INNOVEOX gets Charles Rosier as new Partner and TOTAL EP as first client - Afrik-news.com : Africa news, Maghreb news - The african daily newspaper

A Brief Glimpse at Charles Rosier’s Life

His interests include studies, extreme sports, handling environmentally-friendly activities, exploring culture and many other interests. To be ready for ESCP Europe, charles rosier (site utile) attended two years of additional classes at Integrale. His investment banking took him to various positions in the market. It was in 1996, at Lehman Brothers, when Charles Rosier began his profession before becoming the head of finance at Goldman Sachs Bank, soon after joining UBS Warburg Investment Bank.

Five principles (Client Focus, Long Term View, Global Thinking Presence, Meritocracy and Partnership and World-Class Governance) were put in place by Charles Rosier during his stay at BTG Pactual. He became the Managing Director of Goldman Sachs, from 2009 to 2010. He worked as a partner at BTG Pactual Bank, which has 30 years of experience in international markets, employing more than 2,500 people spread across Latin America. From 1997 to 2009, Charles Rosier was the Debt Capital Manager of SBC Warburg. He also worked at Lehman Brothers where he began his profession as an investment banker.

Job

He has been in the market for 15 years, in the role of investment banker. Charles Rosier finally joined BTG Pactual in August 2010. BTG Pactual is an investment bank in Latin America. He became a partner there. Charles Rosier was offered a job at Goldman Sachs in 1999. He became their Managing Director.

Charles Rosier's first Baccalaureate degree was equivalent to A-levels in the UK. Large companies see him to be a well-experienced banker, who is able to hold different positions in the sector. He took two years of additional classes in preparation for attaining further French qualifications. When Charles Rosier gained his degree at ESCP Europe, it became the gateway to establishing his own career.

Because of the investment made by him, the organisation was able to perform research and give a percentage of their profit to Charles Rosier. He also invested capital in the laboratory of Mapreg, in Paris, to continue doing studies about serious issues including depression and stroke. Whilst in great need for additional funds in developing a new useful drug, Baulieu and his co-workers obtained financial assistance from his investment.